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Abstract
Introduction Little is known about endogenous or cytokine-
stimulated aggrecan catabolism in the meniscal fibrocartilage of
the knee. The objectives of this study were to characterize the
structure, distribution, and processing of aggrecan in menisci
from immature bovines, and to identify mechanisms of
extracellular matrix degradation that lead to changes in the
mechanical properties of meniscal fibrocartilage.
Methods Aggrecanase activity in the native immature bovine
meniscus was examined by immunolocalization of the aggrecan
NITEGE neoepitope. To investigate mechanisms of cytokine-
induced aggrecan catabolism in this tissue, explants were
treated with interleukin-1α (IL-1) in the absence or presence of
selective or broad spectrum metalloproteinase inhibitors. The
sulfated glycosaminoglycan (sGAG) and collagen contents of
explants and culture media were quantified by biochemical
methods, and aggrecan catabolism was examined by Western
analysis of aggrecan fragments. The mechanical properties of
explants were determined by dynamic compression and shear
tests.
Results The aggrecanase-generated NITEGE neoepitope was
preferentially localized in the middle and outer regions of freshly
isolated immature bovine menisci, where sGAG density was
lowest and blood vessels were present. In vitro treatment of
explants with IL-1 triggered the accumulation of NITEGE in the
inner and middle regions. Middle region explants stimulated with
IL-1 exhibited substantial decreases in sGAG content, collagen
content, and mechanical properties. A broad spectrum
metalloproteinase inhibitor significantly reduced sGAG loss,
abrogated collagen degradation, and preserved tissue
mechanical properties. In contrast, an inhibitor selective for
ADAMTS-4 and ADAMTS-5 was least effective at blocking IL-1-
induced matrix catabolism and loss of mechanical properties.
Conclusions Aggrecanase-mediated aggrecanolysis, typical of
degenerative articular cartilage, may play a physiologic role in
the development of the immature bovine meniscus. IL-1-induced
release of sGAG and loss of mechanical properties can be
ascribed primarily to the activity of MMPs or aggrecanases other
than ADAMTS-4 and ADAMTS-5. These results may have
implications for the clinical management of osteoarthritis.
Introduction
The knee menisci have essential roles to play in load transfer
and distribution during joint motion, and partial or complete
meniscectomy initiates degeneration of the adjacent articular
cartilage [1,2]. Meniscal fibrocartilage is rich in circumferen-
tially- and radially-oriented collagen fibrils [3] and extracellular
matrix (ECM) proteoglycans including aggrecan, decorin, and
biglycan [4]. In articular cartilage, aggrecan confers compres-
sive and shear stiffness through its attached sulfated gly-
cosaminoglycan (sGAG) chains [5,6]. Valiyaveettil and
colleagues immunolocalized the G1 domain of aggrecan (the
globular hyaluronan-binding domain) between collagen fibrils
ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs; DAPI: 4',6-diamidino-2-phenylindole dihydrochloride; DMEM: Dulbecco's 
Modified Eagle's Medium; DMMB: dimethylmethylene blue; ECF: enhanced chemifluorescence; ECM: extracellular matrix; FITC: fluoroscein isothio-
cyanate; HEPES: N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid; IL-1: interleukin-1; MMP: matrix metalloproteinases; NBF: neutral buffered 
formalin; NEAA: non-essential amino acids; PBS: phosphate buffered saline; rh: human recombinant; sGAG: sulfate glycosaminoglycans; TNF: tumor 
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in the canine meniscus and proposed that aggrecan dissi-
pates compressive loads in the meniscus [7]. Other fibrocarti-
lages, such as regions of deep flexor tendon, are also enriched
in high molecular weight aggrecan [8].
Meniscal cells exhibit regional differences in morphology and
ECM metabolism [9]. While having similar rates of collagen
synthesis, cells from the inner region of the meniscus exhibit
higher sGAG accumulation rates than cells from the outer
region [10,11]. Regional variations in meniscus sGAG content
apparently result from differences in aggrecan concentration
due in part to regional differences in aggrecan gene expres-
sion [7,12]. Whereas the molecular weight of the full-length
aggrecan core protein is about 450 kDa, an abundance of 66
to 70 kDa-sized aggrecan fragments was identified in extracts
of bovine meniscal fibrocartilage, suggesting that extensive
aggrecan cleavage is normal in this tissue [13]. The size and
C-terminal neoepitope (NITEGE, a peptide sequence exposed
upon proteolytic cleavage) of those fragments indicated that
aggrecanases of the a disintegrin and metalloproteinase with
thrombospondin motifs (ADAMTS) family were responsible for
the observed aggrecan processing [14,15]. Significantly, the
NITEGE neoepitope was also immunolocalized in the menisci
of fetal human joints [16], suggesting that aggrecanolysis dur-
ing development of the menisci is conserved across species.
The implications of this extensive aggrecan cleavage in the
normal immature meniscus are unknown, and regional differ-
ences in the aggrecanase activity of meniscal fibrocartilage
have not yet been described.
The proinflammatory cytokines IL-1α and β are linked to the
onset of arthritis and initiate aggrecanolysis followed by colla-
gen degradation in articular cartilage [17,18]. In vivo, com-
plete loss of sGAG and the onset of collagen damage appear
to mark a degenerative 'point of no return' [19-21]. In IL-1-stim-
ulated bovine articular cartilage explants, aggrecanolysis and
the associated depletion of sGAG are mediated by ADAMTS-
4 and/or -5 (aggrecanase-1 and -2, respectively) and lead to
loss of tissue mechanical properties [22]. ADAMTS-5 knock-
out mice exhibit profound resistance to ECM resorption in in
vivo  models of osteoarthritis [23,24], and pharmacologic
inhibitors of aggrecanases and MMPs can delay or reduce
matrix destruction in IL-1-stimulated bovine articular cartilage
[25-27]. There are few detailed reports describing the
response of fibrocartilage to IL-1 stimulation or the participa-
tion of aggrecanases in the remodeling of fibrocartilage ECM.
IL-1 treatment of explanted rabbit menisci increased nitric
oxide and MMP production [28], and cells from fibrocartilage
of the rat temporomandibular joint exhibited upregulated
expression of MMPs in the presence of IL-1β [29]. IL-1 abro-
gated the biosynthetic response of porcine meniscal cells to
mechanical stimuli [30]. Both IL-1 and TNF-alpha were
recently shown to inhibit the intrinsic repair capacity of
explanted meniscal fibrocartilage, and pharmacologic inhibi-
tion of MMPs partially rescued the repair response [31-34].
However, neither the enzymatic mechanisms responsible for
sGAG release in IL-1-stimulated fibrocartilage nor the IL-1-
induced changes in fibrocartilage mechanical properties have
been previously reported.
The objective of the current study was to identify mechanisms
of aggrecan catabolism in freshly isolated and IL-1-stimulated
immature bovine meniscus. The enzymatic activities of aggre-
canases and MMPs were perturbed using pharmacologic
inhibitors, and tissue degradation was assessed using bio-
chemical assays, western blots, and mechanical tests. The
results indicate that the NITEGE neoepitope accumulated
preferentially in the middle and outer regions of the immature
meniscus, where the sGAG density was lowest and blood ves-
sels were readily detected. IL-1 stimulation of meniscus
explants caused a predominantly matrix metalloproteinase
(MMP)-mediated release of sGAG and loss of mechanical
properties. Collectively, the data indicate that regional varia-
tions in generation of the NITEGE neoepitope is normal in the
developing immature bovine meniscus and cytokine-induced
degradation of the meniscus is mediated primarily by MMPs.
Materials and methods
Reagents and antibodies
DMEM, gentamicin, non-essential amino acids (NEAA), N-(2-
hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES),
trypsin-ethylenediaminetetraacetic acid, proteinase K, PBS
and Alexafluor 488 anti-rabbit and Alexafluor 594 anti-mouse
secondary antibodies were from Invitrogen (Carlsbad, CA,
USA). Antibodies to aggrecan G1 and the NITEGE
neoepitope were prepared as previously described [35]. The
antibody to type I collagen was from Abcam (Cambridge, MA,
USA), and the antibody to bovine decorin (LF-94) was a gift
from Dr. Larry Fischer (National Institute of Dental and Cranio-
facial Research, Bethesda, MD, USA). Fluorescein isothiocy-
anate (FITC)-conjugated secondary antibody was from
Chemicon (Temecula, CA, USA). Guanidine hydrochloride,
chondroitinase ABC, keratanase I, chloramine-T, para-(dimeth-
ylamino)-benzaldehyde (pDAB), non-immune rabbit IgG, alka-
line phosphatase-conjugated secondary antibody, 4',6-
diamidino-2-phenylindole dihydrochloride (DAPI), and other
histologic reagents were from Sigma (St. Louis, MO, USA).
Verhoeff's stain was from Poly Scientific (Bay Shore, NY,
USA). Keratinase II was from Associates of Cape Cod (Fal-
mouth, MA, USA). Dimethylmethylene blue (DMMB) was from
Polysciences (Warrington, PA, USA). Recombinant human IL-
1α (rhIL-1α) was from Peprotech (Rocky Hill, NJ, USA).
Protease inhibitor cocktail I was from Calbiochem (San Diego,
CA, USA). The enhanced chemifluorescence (ECF) substrate
was from Amersham (Piscataway, NJ, USA). Metalloprotein-
ase inhibitors (RO3310769, aggrecanase-1,2-selective;
RO1136222, MMP-selective; RO4002855, broad-spectrum
metalloproteinase) with previously described selectivity pro-Available online http://arthritis-research.com/content/11/6/R173
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files [27] were provided by Roche - Palo Alto (Palo Alto, CA,
USA).
Histology and immunostaining
Immature (one to two weeks) bovine menisci (Research 87,
Cambridge, MA, USA) were harvested aseptically within 24
hours of slaughter. Coronal 'slabs' (3 to 4 mm thick, Figure 1a)
were either fixed in 10% neutral-buffered formalin (NBF) at
4°C for 48 hours and embedded in paraffin or fixed in 10%
NBF for four hours at 4°C, incubated in 30% sucrose/PBS
overnight at 4°C, embedded in optimal cutting temperature
(OCT) embedding medium, and frozen in liquid-nitrogen
cooled isopentane. Paraffin-embedded tissue was sectioned
at 3 μm, stained for sGAG with safranin-O, and counter-
stained with fast green and hemotoxylin. Blood vessels were
identified in sections stained with Verhoeff's elastin stain, dif-
ferentiated in 2% ferric chloride, rinsed in 5% sodium thiosul-
fate, and counterstained with van Gieson's collagen stain.
Frozen tissue was sectioned at 7 μm and co-immunostained
for the aggrecan NITEGE neoepitope and collagen type I.
Sections were digested with 0.5% trypsin for 10 minutes at
37°C and blocked for one hour at room temperature with
blocking buffer containing 2% goat serum, 0.1% gelatin, 1%
bovine serum albumin, 0.1% Triton, and 0.05% Tween-20 in
PBS prior to incubation with antibodies. Primary antibodies
were detected by indirect immunofluoresence with Alexafluor
488- and Alexafluor 594-conjugated secondary antibodies.
Following tissue culture, 3 to 4 mm thick coronal slabs were
fixed in 10% NBF for 48 hours at 4°C, embedded in paraffin,
and sectioned at 3 μm. The NITEGE neoepitope was detected
by indirect immunofluoresence with a goat anti-rabbit FITC-
conjugated secondary antibody. All antibodies were used at
10 μg/mL with incubations for 60 to 90 minutes at room tem-
perature. Cell nuclei were stained with DAPI.
Species-matched non-immune IgGs were used as negative
controls. Images of histochemically stained sections were
captured on a Nikon E600 microscope (Nikon USA, Melville,
NY, USA). Immunofluorescent sections were imaged on a
Zeiss AxioVert 200 M microscope using the Apotome optical
sectioning module (Zeiss, Jena, Germany).
Tissue culture
In a preliminary study, coronal sections (Figure 1a) were dis-
sected from immature bovine menisci and cultured in six-well
plates with or without 20 ng/mL rhIL-1α in serum-free media
consisting of DMEM, 10 mM NEAA, 50 μg/mL gentamicin,
and 50 μg/mL ascorbic acid under standard conditions (5%
CO2, 95% humidity and 37°C). Media were exchanged after
48 hours. After four days, the tissue was fixed and processed
for immunofluorescent detection of the NITEGE neoepitope.
Full-thickness cylindrical specimens (3 mm in diameter) were
harvested from the middle region of menisci and cut to 2 mm
in thickness with superficial tissue excluded (Figure 1b), gen-
erating samples with well-controlled geometries and low vari-
ability in initial wet mass (16.1 ± 1.7 mg). Explants were pre-
cultured for 72 hours in 0.5 mL of 'basal' serum-free media
consisting of DMEM, 10 mM NEAA, 50 μg/mL gentamicin,
and 50 μg/mL ascorbic acid, followed by up to 12 days with
or without 20 ng/mL rhIL-1α. Some explants were additionally
treated with 20 μM of the aggrecanase-selective inhibitor, 5
μM of the MMP-selective inhibitor, or 5 μM of the broad-spec-
trum metalloproteinase inhibitor (doses based on previous
studies [27]). Media were exchanged every 48 hours. Explants
(n = 6 per group) were collected at days 0, 4, 8, and 12 days
of culture and stored frozen in PBS with protease inhibitors.
Day 0 and 8 explants were lyophilized and extracted for 48
hours at 4°C in 10 volumes of extraction buffer (4 M guanidine
hydrochloride, 10 mM 2-(N-morpholino)ethanesulfonic acid,
50 mM sodium acetate, 5 mM ethylenediaminetetraacetic
acid, 5 mM iodoacetic acid at pH 6.5) with protease inhibitors.
Mechanical testing
Day 0 and day 12 explants were thawed, weighed, and meas-
ured using digital calipers. All tests were performed in PBS
with protease inhibitors after compression by 10% of the
explant thickness and 12 minutes of stress relaxation. Explants
were tested in torsional shear on a CVO120 rheometer (Boh-
lin, East Brunskwick, NJ, USA) with a 0.5% nominal shear
strain at 0.001 to 0.1 Hz to determine dynamic shear moduli
G*. Following equilibration to the free-swelling state, the sam-
ples were recompressed and tested in oscillatory unconfined
compression on an ELF3200 (Enduratec, Minnetonka, MN,
USA) with a 1.5% strain amplitude at 0.001 to 0.1 Hz to deter-
mine the dynamic compressive moduli E*.
Biochemistry
Explants from day 0, 4, and 12 were lyophilized, weighed, and
digested in 0.0125 mg/mg tissue proteinase K. Explant
digests, explant extracts, and conditioned media were
assayed for sGAG content by the DMMB dye-binding method
[36]. Digests and conditioned media were assayed for hydrox-
yproline content by the chloramine-T/pDAB reaction [37], with
Figure 1
Immature bovine menisci Immature bovine menisci. (a) Coronal sections were harvested from 
immature bovine menisci for histologic and immunofluorescence analy-
sis and the preliminary tissue culture experiments. (b) Cylindrical 
explants from the middle region were prepared for the inhibitor study.Arthritis Research & Therapy    Vol 11 No 6    Wilson et al.
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collagen content calculated by assuming a collagen:hydroxy-
proline mass ratio of 8:1 [38].
Western blotting
The inner (about 5 mm), middle (about 5 mm), and outer
(about 8 mm; along lines drawn in Figure 1a) of immature
bovine menisci were dissected, minced, and extracted in
extraction buffer (80 mg wet tissue per ml) for 48 hours at 4°C.
Conditioned media from the inhibitor study were pooled from
days 2 and 4, 6 and 8, or 10 and 12 (from six explants per con-
dition), and equal portions of day 0 and day 8 explant extracts
were pooled (six explants per condition and time point). Prote-
oglycans were isolated from the media and extracts by ethanol
precipitation, dried, and deglycosylated by overnight digestion
in chondroitinase ABC and keratanases I and II. Equal volumes
of conditioned media or native tissue extracts, or equal quan-
tities of sGAG (5 μg for explant extracts), were separated by
electrophoresis and transferred to nitrocellulose. Blotting
equal volumes of media or tissue extract afforded direct com-
parison of the abundance per wet weight of the proteins of
interest. Blotting equal amounts of sGAG (as with explant
extracts) allowed comparison of the abundance of sGAG-
bearing proteins per μg total sGAG. Following blocking, mem-
branes were probed with primary antibodies at 1 μg/mL. Blots
were developed using an alkaline phosphatase secondary
antibody and exposure to ECF. Bands were visualized using a
Fuji FLA3000 (Fuji, Tokyo, Japan).
Statistics
The main effects of inhibitor treatments (at each time point)
were evaluated using a general linear model in MINITAB
Release 14 (MINITAB, States College, PA, USA). Pairwise
comparisons between groups were determined by Dunnett's
test with IL-1-only treated samples as controls and signifi-
cance at P < 0.05.
Results
Regional variations in sGAG content and the 
aggrecanase-generated NITEGE neoepitope in the 
immature meniscus
Safranin-O staining revealed marked regional variations in
sGAG content within the immature meniscus with the most
intense staining within the inner region (Figure 2a). There were
also sGAG-rich pockets in the middle and outer regions colo-
calized with cells and between collagen fibril bundles. These
patterns are consistent with previously reported regional vari-
ations in canine meniscus aggrecan content [7], porcine
aggrecan gene expression [12], and ovine proteoglycan syn-
thesis rates [39]. Verhoeff's stain demonstrated the presence
of blood vessels in the middle and outer regions of the imma-
ture meniscus. Vessels were identified by elastin staining
(black) and the presence of open lumens. The inner region
was consistently devoid of blood vessels.
The abundance of the aggrecan NITEGE neoepitope, a prod-
uct of aggrecanase activity, varied across coronal sections of
the immature meniscus (Figure 2a, lower panels), with weak
staining in the inner region but intense intra- and peri-cellular
staining in the middle and outer regions. The middle and outer
regions also exhibited NITEGE staining along and within colla-
gen fibril bundles. NITEGE appeared in regions where
safranin-O staining was weak and blood vessels were present.
Immunoblots of tissue extracts (Figure 2b) supported the
staining patterns, demonstrating regional variations in the
abundance of NITEGE in both medial and lateral menisci.
Localization of the NITEGE neoepitope in IL-1-
stimulated meniscal fibrocartilage
When cultured coronal sections of meniscus were examined
by immunohistochemistry, the unstimulated controls showed
regional variations in NITEGE abundance similar to freshly iso-
lated tissue and an increase in staining in the surface zone of
the inner region (Figure 3). In contrast, IL-1-stimulated tissue
exhibited marked increases in NITEGE staining throughout the
inner and middle regions. The middle region of IL-1-stimulated
meniscus demonstrated enhanced NITEGE staining around
fibril bundles, seen as a brightly stained fine network that was
less intense in the inner region and absent from the outer
region. These data indicate that IL-1 stimulation of immature
meniscal fibrocartilage triggers the exposure of the NITEGE
neoepitope, presumably through aggrecanase-mediated deg-
radation of aggrecan.
IL-1-induced release of sGAG and aggrecan processing 
in the immature meniscus
IL-1 stimulation triggered significant, time-dependent reduc-
tions in the sGAG content of meniscal explants (Figure 4a).
Inhibition of aggrecanase-1 and -2 did not significantly
enhance sGAG retention relative to IL-1-only controls at either
day 4 or 12. Conversely, explants treated with an MMP-selec-
tive inhibitor exhibited sGAG depletion similar to IL-1-only con-
trols over days 0 to 4 but had significantly higher sGAG
contents than IL-1-only controls at day 12. Explants treated
with a broad-spectrum inhibitor exhibited a blunted acute IL-1-
induced release of sGAG and maintained significantly higher
sGAG contents than IL-1-only controls at days 4 and 12.
These data suggest that aggrecanases-1 and -2 participate in
the early release of sGAG in response to IL-1, but MMPs and/
or other aggrecanases contribute substantially to the release
of sGAG later in the degradative process.
The size and structure of aggrecan in meniscal explants from
day 0 and 8 were examined by western blot for the aggrecan
G1 domain (Figure 4b). The sGAG contents of day 8 explant
extracts (Figure 4b, lower panel) are provided for reference
and are consistent with the temporal trajectories of explant
digest sGAG content depicted in Figure 4a. A doublet migrat-
ing at 66 to 70 kDa was an abundant product in explant
extracts and confirmed as the G1-NITEGE fragment in blotsAvailable online http://arthritis-research.com/content/11/6/R173
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for the NITEGE neoepitope (not shown). The blot reveals a
paucity of high molecular weight aggrecan at day 0 (and later
culture times), although this may be attributable to relatively
poor extraction of sGAG-bearing proteoglycans from the
explants. We previously found that (with the guanidine extrac-
tion buffer used in the present study) proteoglycans are more
difficult to extract from meniscal fibrocartilage than from age-
and species-matched articular cartilage [40]. Over the course
of eight days in culture, the abundance of 66 to 70 kDa aggre-
can increased slightly in untreated explants and was markedly
reduced in IL-1-treated tissue. The aggrecanase-1,2-selective
inhibitor had little effect on the IL-1-induced depletion of this
species, whereas both the MMP-selective and broad-spec-
trum inhibitors abrogated this effect of IL-1 on the explants,
suggesting that MMPs mediate the release of aggrecan-G1
from IL-1-stimulated meniscal fibrocartilage.
We also examined the abundance of the small leucine-rich
proteoglycan decorin in the explant extracts (Figure 4b, middle
panel). Decorin was readily detected in untreated controls but
was almost absent in IL-1-stimulated explants. Interestingly,
treatment with any of the metalloproteinase inhibitors abol-
ished the IL-1-induced depletion of decorin. These results
underscore the susceptibility of other proteoglycans to IL-1-
induced ECM catabolism, and suggest that some sGAG
released from the explants is associated with non-aggrecan
proteoglycans.
Assays of conditioned media confirmed that IL-1 stimulated
the release of sGAG and aggrecan from meniscal fibrocarti-
lage (Figure 5). Release of sGAG peaked early in the experi-
ment (days 0 to 4) and was substantially lower at later
timepoints (Figure 5a). The amount of sGAG released from
unstimulated controls was about 50% of that released from IL-
1-treated explants. None of the inhibitor treatments signifi-
cantly reduced IL-1-induced sGAG release over the first 96
hours, but treatment with the MMP-selective or broad-spec-
trum inhibitors significantly reduced sGAG in the media at
later time points.
Figure 2
Regional variations in proteoglycan content, vasculature, and aggrecanase product abundance (G1-NITEGE) in freshly isolated immature bovine  meniscus Regional variations in proteoglycan content, vasculature, and aggrecanase product abundance (G1-NITEGE) in freshly isolated immature bovine 
meniscus. (a) Coronal sections of medial meniscus stained for sulfated glycosaminoglycan (red = safranin-O stain; counterstained with fast green), 
elastin (black = Verhoeff's stain; pink = van Gieson's stain for collagen), or the aggrecan NITEGE neoepitope (green) and collagen type I (red). In 
immunofluorescent images, the cell nuclei are blue. Inner, middle, and outer refer to the radial position in the coronal plane. Scale bars = 100 μm. (b) 
The regional variations in aggrecan NITEGE abundance were confirmed by western blot of tissue extracts of both lateral (left lanes) and medial (right 
lanes) menisci. Equal volumes of tissue extracts (each from about 5 mg wet mass tissue) were loaded in each lane. The migration of globular protein 
standards are shown at left.Arthritis Research & Therapy    Vol 11 No 6    Wilson et al.
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Figure 3
Localization of the NITEGE neoepitope in immature meniscus in the absence and presence of IL-1 Localization of the NITEGE neoepitope in immature meniscus in the absence and presence of IL-1. Aggrecan NITEGE (green) detected in untreated 
(top) and IL-1-stimulated (bottom) meniscal fibrocartilage. Cell nuclei are blue. Inner, middle, and outer refer to the radial position in the coronal 
plane. Scale bar = 100 μm.
Figure 4
Inhibition of IL-1-induced proteoglycan depletion in immature meniscal fibrocartilage Inhibition of IL-1-induced proteoglycan depletion in immature meniscal fibrocartilage. (a) Sulfated glycosaminoglycan (sGAG) contents of middle-
zone meniscal fibrocartilage explants. § †, and ‡ indicate P < 0.05 vs. IL-1 for IL-1 + matrix metalloproteinases (MMP) inhibitor, IL-1 + broad-spec-
trum inhibitor, and untreated, respectively. (b) Aggrecan G1 fragments and decorin core protein in day 0 and day 8 explants. A 5 μg sample of 
extracted sGAG, pooled from six explants per condition, were loaded in each lane. The doublet migrating at about 65 kDa was confirmed as the G1-
NITEGE product (not shown). The migration of globular protein standards are shown at left. Below blots are sGAG contents of the explant extracts 
from day 8.Available online http://arthritis-research.com/content/11/6/R173
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Using antibodies to the G1 domain and the NITEGE
neoepitope, various aggrecan fragments were detected in the
conditioned media (Figure 5b). Untreated controls released
high molecular weight species at about 400 kDa (full-length
aggrecan), about 280 kDa, and about 250 kDa as well as a
low molecular weight species migrating at about 70 kDa and
bearing the NITEGE neoepitope (Figure 5b, lower panels).
Media from IL-1-stimulated samples contained the 250 kDa
G1 species and the 66 to 70 kDa NITEGE doublet found in
media from unstimulated controls, as well as additional G1
species migrating at about 100 kDa and about 45 kDa. Previ-
ous work with the anti-G1 antibody has shown that the 45 kDa
band is due to reactivity with link protein [15]. The bulk of
aggrecan G1 was released from IL-1-stimulated fibrocartilage
within the first 96 hours, when a large fraction of sGAG was
released to the media. Treatment with the aggrecanase-1,2-
selective inhibitor diminished the IL-1-induced release of the
250 kDa G1 species and NITEGE-bearing fragments to media
over the first 96 hours, and abolished release of the 100 kDa
and 45 kDa G1 species. The MMP-selective inhibitor also
appeared to diminish aggrecan release to the media, but this
inhibitor did not block release of the 100 kDa or 45 kDa spe-
cies and release of NITEGE was similar to IL-1-only controls.
Significantly, the broad-spectrum inhibitor restored the tempo-
ral pattern of aggrecan (G1 and NITEGE) release in IL-1-stim-
ulated explants to that of unstimulated controls.
Inhibition of IL-1-induced collagen degradation in the 
immature meniscus
Assays of explant digests demonstrated that IL-1 triggered a
loss of collagen (Figure 6a), and treatment with either the
MMP or broad-spectrum metalloproteinase inhibitor abolished
IL-1-induced collagen degradation. Unstimulated controls
exhibited low rates of collagen release, and IL-1-stimulation
elevated release from day 6 to 12 (Figure 6b). Addition of the
aggrecanase-1,2-selective inhibitor did not affect collagen
release, consistent with its specific effects on ADAMTS-4 and
-5, which have no proteolytic activity against collagen. Interest-
ingly, this pattern is in contrast to articular cartilage, where
aggrecanase inhibition delayed the onset of IL-1-induced col-
lagen destruction [26,27] presumably by blocking access of
the MMPs to the collagen rather than through direct MMP inhi-
bition. Treatment with the MMP-selective or broad spectrum
metalloproteinase inhibitors potently inhibited IL-1-induced
collagen depletion in meniscal explants, confirming that MMPs
were primary mediators of collagen destruction in this culture
system.
Inhibition of IL-1-induced loss of mechanical properties 
in the immature meniscus
In both unconfined compression and torsional shear tests, day
0 tissue exhibited trends of increasing modulus with fre-
quency, and these trends were maintained in unstimulated
controls following 12 days of culture (Figure 7). Significantly,
the compression and shear properties of these explants were
maintained over 12 days of culture, despite evidence of per-
sistent aggrecanolysis (Figures 4 and 5), suggesting that gen-
eration of NITEGE in the immature bovine meniscus is
compatible with maintenance of this tissue's mechanical prop-
erties (perhaps due to contributions by proteoglycans other
than aggrecan). Stimulation with IL-1 led to reductions in both
compression and shear moduli, and the aggrecanase- and
Figure 5
Sulfated glycosaminoglycan (sGAG) and aggrecan release from meniscal fibrocartilage to conditioned media Sulfated glycosaminoglycan (sGAG) and aggrecan release from meniscal fibrocartilage to conditioned media. (a) Media from day 12 explants were 
pooled by time points (days 2 + 4, 6 + 8, and 10 + 12) and assayed for sGAG by the dimethylmethylene blue (DMMB) assay. Data are mean + 
standard error of the mean with n = 6. § indicates P < 0.05 vs. IL-1. (b) Media were then blotted for aggrecan G1 fragments and NITEGE 
neoepitope. Equal volumes of media, pooled from six explants per condition, were loaded in each lane. Lane 1 = media pooled from days 2 + 4; Lane 
2 = media pooled from days 6 + 8; Lane 3 = media pooled from days 10 + 12. Migration of protein standards are shown at left. In lower panels, 
arrowheads indicate migration of the 64 kDa molecular weight marker. Note that the early sGAG release data from day 12 explants should not be 
quantitatively compared with the day 4 residual sGAG contents (Figure 4a) from different explants. MMP = matrix metalloproteinases.Arthritis Research & Therapy    Vol 11 No 6    Wilson et al.
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MMP-selective inhibitors did not significantly ameliorate these
losses. IL-1-stimulated explants cultured with the broad-spec-
trum inhibitor, however, had significantly higher compression
and shear moduli than IL-1-only controls.
Discussion
The results of this study demonstrate regional variations in the
accumulation of aggrecanase-generated aggrecan fragments
in the developing bovine meniscus. In articular cartilage, the
NITEGE neoepitope is indicative of tissue degeneration and is
essentially undetected in immature tissue. In contrast, exten-
sive proteolytic processing of aggrecan, yielding products
found in degenerative articular cartilage, appears to be normal
in the developing meniscus. NITEGE was abundant in the mid-
dle and outer zones of immature meniscal fibrocartilage (as
previously reported [13]) and was steadily released from mid-
dle zone explants over 12 days in culture. Interestingly,
safranin-O staining is more uniformly distributed and aggrecan
gene expression is higher in menisci from mature animals than
from immature animals, suggesting that these regional varia-
Figure 7
Inhibition of IL-1-induced loss of meniscal explant dynamic (a) compression and (b) shear moduli by metalloproteinase inhibitors Inhibition of IL-1-induced loss of meniscal explant dynamic (a) compression and (b) shear moduli by metalloproteinase inhibitors. Explants from day 0 
and 12 were tested in oscillatory unconfined compression and torsional shear. Data are mean + standard error of the mean, n = 6. ‡ indicate P < 
0.05 vs. IL-1. MMP = matrix metalloproteinase.
Figure 6
Inhibition of IL-1-induced collagen (a) release to media and (b) loss from immature middle-zone meniscal explants by metalloproteinase inhibitors Inhibition of IL-1-induced collagen (a) release to media and (b) loss from immature middle-zone meniscal explants by metalloproteinase inhibitors. 
Data are mean ± standard error of the mean with n = 6. †, ‡, and # indicate P < 0.05 vs. IL-1 for untreated, IL-1 + matrix metalloproteinase (MMP) 
inhibitors, and IL-1 + broad-spectrum inhibitors, respectively.Available online http://arthritis-research.com/content/11/6/R173
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tions in aggrecan density and turnover are dependent on
developmental stage [3]. Although synthesis of proteoglycans
can be regulated at the transcriptional (mRNA) level, regional
variations in immature meniscus sGAG content may be due in
part to regional differences in aggrecanase activity.
Blood vessels were readily detected in the middle and outer
regions of the immature meniscus, but absent in the inner
region, suggesting a spatial relation between vascular supply
and aggrecan destruction in this tissue. It has been suggested
that the vasculature and greater oxygen tension of the outer
meniscus can suppress cartilage-like matrix formation [41],
and preservation of a chondrogenic phenotype similar to inner
region cells may be contingent upon a hypoxic environment
[42]. Further, age-related spatiotemporal changes in meniscal
vascular density are consistent with the inversely related
changes in sGAG localization, because the early post-natal
human meniscus is vascularized throughout while the mature
(over 20 years) meniscus is vascularized only in the outer 25
to 33% [43]. Aggrecanolysis may thus be regulated by access
to the meniscal vascular supply or, conversely, serve to regu-
late vascular persistence in the meniscus. Interestingly, the fat
pads of developing mice and the flexor tendons from young
and mature bovines were also found to contain NITEGE-bear-
ing aggrecan [44,45], suggesting that degradation of aggre-
can has physiologic functions in other vascularized tissues as
well.
Regional differences in mechanical loading may contribute to
the spatial pattern of aggrecanolysis in the meniscus. Finite
element models predict substantial regional variations in com-
plex combinations of compressive, tensile, and shear strains
during physiologic loading [46]. Regions of bovine flexor ten-
don that undergo primarily tensile loading in vivo synthesized
less high molecular weight proteoglycan than explants of com-
pressed tendon [47]. In addition, cells from the inner and outer
regions of the meniscus exhibited distinct biosynthetic
responses to biaxial mechanical loading [48]. It is likely that
interactions between soluble and mechanical factors regulate
aggrecanolysis in the meniscus, and may contribute to the
development of a mechanically appropriate ECM. Extensive
aggrecan cleavage may be necessary for the assembly of
large tension-bearing collagen fibrils in the middle and outer
regions of the meniscus, especially if proper alignment of the
collagen fibrils is a cell adhesion-dependent process. Aggre-
can inhibits nerve outgrowth partly due to the presence of
sGAG, and perineuronal nets are composed of aggrecan
[49,50]. It is possible that meniscal cells, particularly in the
middle and outer regions, would not attach to the ECM or
retain a stellate morphology in the presence of full-length
aggrecan. There is a direct relation between rounded cell mor-
phology and sGAG abundance in articular cartilage and in the
developing meniscus. Maintenance of the stellate morphology
may be essential for fibrocartilage-specific mechanotransduc-
tion pathways, which in turn regulate ECM remodeling.
IL-1-stimulated menisci stained intensely for NITEGE in the
inner and middle regions, where sGAG density was initially
highest. These results may actually underestimate the abun-
dance of NITEGE generated in the meniscus because the sur-
face zones of this tissue (removed for the explant experiment)
appear to have robust aggrecanase activity (Figure 3), consist-
ent with previously reported elevation of MMP-3 expression,
aggrecanase activity, and sGAG release from IL-1-treated sur-
face-zone meniscal fibrocartilage from mature bovines [51].
The sGAG release observed in the current explant study was
likely due to the degradation and/or release of aggrecan as
well as other proteoglycans. Because the G1-NITEGE frag-
ment of aggrecan, abundant in the immature meniscus, lacks
sGAG attachment regions, the contribution of this species to
sGAG content and release would be negligible. sGAG was
detected in conditioned media throughout the culture period,
but high molecular weight aggrecan G1 species were absent
from conditioned media collected late in the experiment, sug-
gesting that other proteoglycans contributed to the release of
sGAG, particularly at later stages of degradation. IL-1 induced
the loss of decorin in this study, and meniscal cells from the
immature rabbit express mRNA for another large proteogly-
can, versican [52]. In addition, decorin, biglycan, fibromodulin,
and versican have been immunolocalized in fibrocartilage of
the intervertebral disc [53], suggesting that a variety of large
and small proteoglycans contribute to the pool of sGAG in the
ECM of fibrocartilages. It is important to note that sGAG-bear-
ing aggrecan may be retained within fibrocartilage independ-
ent of G1-hyaluronan interactions. Vogel and colleagues
detected sGAG-bearing aggrecan lacking the G1 domain in
regions of tendon that undergo tensile loading [8], and we
have recently reported that multiple aggrecan G3 fragments
accumulate in immature meniscal fibrocartilage [40]. The G3
domain can bind ECM proteins such as fibulin and tenascin-C
[54,55], and such interactions could facilitate retention of
aggrecan in the meniscus.
The mechanical functions of meniscal fibrocartilage depend
on the composition, integrity, and organization of its ECM [56].
Explanted meniscal fibrocartilage stimulated with IL-1 for 12
days contained 44% and 67% of the sGAG and collagen,
respectively, in day 0 tissue. Correspondingly, the depleted
tissue retained only 15 to 40% of the shear stiffness and 15 to
22% of the compressive stiffness of the fresh tissue. Explants
treated with the MMP inhibitor retained 100% of the initial col-
lagen but only 63% of the initial sGAG. This reduction in
sGAG was associated with a 53 to 57% reduction in shear
stiffness and a 53 to 61% reduction in compressive stiffness,
indicating that despite comprising a quantitatively minor ECM
constituent (1 to 3% by dry weight) [57], proteoglycans con-
tribute substantially to the shear and compression properties
of immature bovine meniscal fibrocartilage.
Aggrecanases were mediators of aggrecan proteolysis in the
immature meniscus, as evidenced by an abundance ofArthritis Research & Therapy    Vol 11 No 6    Wilson et al.
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NITEGE in tissue extracts. In contrast, MMPs did not appear
to contribute substantially to aggrecanolysis in this system
because characteristic MMP-generated aggrecan fragments
(identified by G1 bands migrating at about 55 kDa) were not
detected in tissue extracts or conditioned media. MMPs did,
however, appear to play a strong role in sGAG release from
meniscal explants. IL-1-induced loss of sGAG was signifi-
cantly reduced by treatment with an MMP-selective inhibitor or
a broad-spectrum (aggrecanase and MMP) inhibitor but not
with an aggrecanase-1,2-selective inhibitor. The selectivities
of these inhibitors for aggrecanases other than aggrecanase-
1 or -2 (e.g., ADAMTS-1, -8, -9, -15, -16, and -18) are
unknown, making it difficult to fully distinguish between the
contributions of MMPs and aggrecanases other than
ADAMTS-4 or -5 to the release of sGAG in these experiments.
However, in a similar model of tissue resorption with age- and
species-matched articular cartilage, ADAMTS-4 and -5 medi-
ated 90% of the observed aggrecanase activity and loss of
sGAG [58]. ADAMTS-5 was found to be the dominant aggre-
canase in mouse models of arthritis [23,24], and a recent
report indicates that ADAMTS-8, -15, -16, and -18 are
expressed at very low levels in mouse cartilage [59].
MMPs may regulate sGAG release by disrupting the aggre-
can-hyaluronan aggregate. IL-1-induced depolymerization of
hyaluronan by free radicals or hyaluronidases, shown to occur
in articular cartilage [60,61], may be influenced indirectly by
MMP activity (or the inhibitors used here). Link protein, which
stabilizes the interaction between aggrecan G1 and hyaluro-
nan, is a substrate for MMP-3 [62], and CD44, a hyaluronan
receptor, is a substrate for MMP-14 [63]. Release of sGAG
from IL-1-stimulated fibrocartilage may be further regulated by
MMP-mediated collagen degradation. The organized bundles
of collagen fibrils in fibrocartilage may demarcate a metabolic
pool of aggrecan for which release is rate-limited by reaction
of MMPs with collagen. Akin to the fascicular structures
present in tendon and muscle, these structures appear to con-
tain relatively thick fibril bundles. Presumably, MMP-mediated
disruption of the fascicular structures would enhance diffusion
of collagen-associated aggrecan out of these structures.
MMPs thus appear to serve an indirect, but quantitatively sig-
nificant, role in the release of aggrecan and sGAG from the
cytokine-stimulated immature meniscus.
Conclusions
Clinical and basic research over the past two decades has
demonstrated the importance of the menisci in the mainte-
nance of healthy knee joint mechanics. Whereas articular car-
tilage has been the subject of intense research in the context
of joint degeneration, subtle changes in meniscal composition
may be more closely associated with the true 'onset' of knee
osteoarthritis [52]. The results of this study indicate that
meniscal fibrocartilage exhibits regional variations in aggrecan
turnover that may be important for normal development of the
tissue. In addition, whereas aggrecanases were the primary
mediators of aggrecanolysis in the meniscus, the release of
sGAG from this tissue appears to be mediated primarily by
MMPs or aggrecanases other than ADAMTS-4 and -5. These
results may have relevance for the clinical management of joint
disease, as understanding the ECM remodeling events driving
normal development and cytokine-induced degradation of the
meniscus will be helpful in developing strategies for repairing
injured and diseased meniscal fibrocartilage.
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